We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Theratechnologies Inc | NASDAQ:THTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.76% | 1.32 | 0.94 | 1.33 | 1.32 | 1.23 | 1.32 | 23,124 | 01:00:00 |
To register for the webinar, please go to: https://lifesci.rampard.com/WebcastingAppv5/Events/Registration/registration.jsp?Y2lk=MTE5MQ==.
The webinar will feature a presentation by KOL Richard Béliveau, Ph.D., Université du Québec à Montréal, who will discuss the science of receptor-mediated cancer therapy and the discovery of sortilin as a novel target in cancer treatment. Dr. Béliveau will be available to answer questions following the formal presentations. Theratechnologies' President and Chief Executive Officer Paul Lévesque and Senior Vice President and Chief Medical Officer Christian Marsolais, Ph.D. will also give an update on its oncology program.
SORT1+ Technology™ is a new class of cancer treatment targeting all sortilin-expressing cancers by linking approved anticancer drugs to a proprietary peptide that specifically binds to the sortilin receptor. The PDC is internalized by the sortilin receptor and the therapeutic agent is released directly inside the cancer cell.
TH1902 was granted fast track designation by the U.S. Food and Drug Administration (FDA) as a single agent for the treatment of all advanced solid tumors expressing sortilin that are refractory to standard therapy and is currently being evaluated in a Phase 1 clinical trial.
About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
For media inquiries:Denis BoucherVice-President, Communications and Corporate Affairs514-336-7800
For investor inquiries:Leah GibsonSenior Director, Investor Relationsir@theratech.com617-356-1009
1 Year Theratechnologies Chart |
1 Month Theratechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions